This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Bone and Articular Cartilage of Limbs사지의 뼈 및 관절연골의 악성신생물 (사지골암)

📋 Contents and key points
A. Classification codesICD-10 C40 (C40.0 scapula and long bones of upper limb, C40.1 upper part of upper limb, C40.2 lower part of upper limb, C40.3 upper part of lower limb, C40.8 overlapping lesion, C40.9 bone of limb, unspecified)
B. SynonymsLimb bone cancer, osteosarcoma of the limbs, Ewing sarcoma of the limbs, chondrosarcoma of the limbs, primary malignant bone tumor of the limbs, bone cancer (limbs)
C. Adult onsetNot low — occurs in both adolescents and adults; osteosarcoma and Ewing sarcoma are most common in the teens to 30s, chondrosarcoma in the 40s to 70s
Special Copayment ReductionV193 · 5 years from the cancer patient registration date · 5% copayment
1. HistoryHistory of osteosarcoma; James Ewing's description of Ewing sarcoma (1921); introduction of chemotherapy ushering in the era of limb-sparing surgery
2. CausesUnknown cause (in most cases); radiation exposure; Paget disease; hereditary syndromes (Li-Fraumeni, retinoblastoma); rate of skeletal growth
3. GeneticsRB1, TP53 (osteosarcoma); EWSR1-FLI1 fusion (Ewing sarcoma); IDH1/2, CDKN2A (chondrosarcoma); CDK4/MDM2 (liposarcoma)
4. EpidemiologyPrimary bone tumors are rare; osteosarcoma is most common in adolescents in their teens to 20s; Ewing sarcoma in the teens to 20s; chondrosarcoma in middle-aged adults
5. PathophysiologyAbnormal proliferation of osteoblasts during periods of active bone growth; RB1/TP53 inactivation; aberrant transcriptional activation by EWSR1-FLI1
6. SymptomsLocal pain (including night pain), swelling, limited joint motion; pathologic fracture; fever (Ewing sarcoma)
7. SignsLocal mass, tenderness, increased skin temperature, venous dilation; elevated alkaline phosphatase; radiographic findings (sunburst pattern)
8. ScreeningNo standard screening test; early MRI in families with hereditary syndromes; imaging evaluation for abnormal orthopedic pain
9. DiagnosisX-ray, MRI, CT, PET-CT; bone biopsy; ALP, LDH blood tests; EWSR1 FISH; IDH mutation testing; AJCC TNM staging
10. TreatmentSurgery (limb-sparing surgery in 90%); neoadjuvant chemotherapy (MAP regimen); radiation (Ewing sarcoma); resection of lung metastases; denosumab (chondrosarcoma)
11. Prognosis5-year survival of localized osteosarcoma 60–70%; localized Ewing sarcoma 70%; metastatic 20–30%; chondrosarcoma favorable with complete resection
12. PreventionMinimize radiation exposure; genetic counseling for hereditary syndromes; management of Paget disease; recognition of early symptoms and prompt access to medical care
13. ReferencesNCI PDQ, NCCN osteosarcoma guidelines, Moffitt, related literature in Frontiers in Oncology

1. History

Primary malignant tumors arising in the bone and articular cartilage of the limbs are rare but are important malignant diseases in adolescents and young adults. For osteosarcoma, the most common primary malignant bone tumor, surgical amputation was the main treatment from the late 19th century. In the early 19th century, amputation was the only treatment option, and the 5-year survival rate was less than 15–20%.

In 1921, James Ewing described a tumor then called 'endothelioma of bone', establishing Ewing's sarcoma as a separate pathological entity. Ewing sarcoma was known early on to be sensitive to radiation therapy, and from the 1920s to the 1960s radiation therapy was the main treatment.

A revolutionary change in the treatment of osteosarcoma began in the 1970s with the introduction of combination chemotherapy. As Gerald Rosen, Norman Jaffe and others developed combination chemotherapy (the MAP regimen) using high-dose methotrexate, doxorubicin, and cisplatin, the 5-year survival rate improved dramatically from 15% to 60–70%. More importantly, with the introduction of neoadjuvant chemotherapy, tumors could be shrunk before surgery, so that instead of the limb amputation that was previously unavoidable, limb-sparing surgery became possible. Currently, limb-sparing surgery is performed in about 90% of patients with osteosarcoma.

In Korea as well, limb-sparing surgery and combination chemotherapy were introduced from the 1980s–1990s, markedly improving treatment outcomes, and treatment now meets international standards.

2. Causes

For most primary malignant bone tumors, the exact cause is unknown (idiopathic). However, several risk factors have been identified.

Radiation exposure

Exposure to ionizing radiation is a risk factor for secondary osteosarcoma. Radiation-induced osteosarcoma can develop in bone that has long been included in the radiation therapy field, usually after a latency period of 10–20 years following radiation exposure. There are also historical reports of a high risk of osteosarcoma in workers exposed to radioactive substances (radium, strontium, etc.).

Genetic factors and syndromes

Li-Fraumeni syndrome: germline TP53 mutations markedly increase the risk of various malignancies (osteosarcoma, soft tissue sarcoma, breast cancer, etc.). Hereditary retinoblastoma: due to germline RB1 mutations, the risk of osteosarcoma after cure of retinoblastoma increases by several tens of times. Werner syndrome: mutations in a DNA repair gene (WRN helicase) increase the risk of osteosarcoma along with premature aging. In addition, the risk of osteosarcoma is increased in DNA repair disorder syndromes such as Rothmund-Thomson syndrome and Bloom syndrome.

Bone diseases

Paget's disease of bone is a disorder of bone remodeling and, although rare, is a risk factor for secondary osteosarcoma. Paget-associated osteosarcoma, which occurs mainly in the elderly, has a very poor prognosis. Bone infarction and chronic osteomyelitis can also rarely be the background for secondary malignant transformation.

Rapid bone growth

The predilection of osteosarcoma for the adolescent growth spurt suggests that rapid bone growth and increased osteoblast activity may contribute to carcinogenesis. Epidemiological studies showing a relatively higher risk of osteosarcoma in tall adolescents support this.

3. Genetics

Genetics of osteosarcoma

Osteosarcoma has a complex genome, with multiple genomic changes involved in combination rather than a single specific mutation. Biallelic inactivation of RB1 (Retinoblastoma gene) (about 70%) and TP53 mutations (about 60%) are the most important genetic abnormalities. Simultaneous inactivation of these two tumor suppressor genes leads to impaired cell cycle regulation. The high frequency of osteosarcoma in patients with hereditary retinoblastoma clearly shows the role of germline RB1 mutations. Additional mutations such as CDKN2A, DLG2, ATRX and complex karyotypic rearrangements are characteristic.

Genetics of Ewing sarcoma

The most characteristic genetic abnormality of Ewing sarcoma is the EWSR1-FLI1 fusion gene, formed by the t(11;22)(q24;q12) chromosomal translocation in about 85% of cases. The rest show variant fusions such as EWSR1-ERG, EWSR1-ETV1, and EWSR1-ETV4. The EWSR1-FLI1 fusion protein acts as a transcription factor that aberrantly activates or represses the expression of hundreds of genes, causing the tumor. This genetic abnormality is a diagnostic marker of Ewing sarcoma and central to targeted therapy research.

Genetics of chondrosarcoma

The most common mutations in chondrosarcoma are IDH1 (R132H, etc.) and IDH2 mutations (about 30–60%), which cause epigenetic abnormalities through production of 2-hydroxyglutarate (2-HG). CDKN2A deletion and COL2A1 mutations are also characteristic genetic abnormalities of chondrosarcoma.

4. General epidemiology

Primary malignant bone tumors are rare, accounting for about 0.2% of all malignancies. About 3,500 primary malignant bone tumors occur annually in the United States, and several hundred cases are estimated to occur annually in Korea.

Osteosarcoma is the most common primary malignant bone tumor (about 35%), with an incidence of about 3–5 per million per year. The median age at onset is about 15 years, and it occurs most often in adolescence (ages 10–20). A second peak appears in the elderly aged 60 or older, many of which are Paget disease-associated or radiation-induced secondary osteosarcomas. Ewing sarcoma is the second most common malignant bone tumor (about 16%), occurring mainly in adolescents in their teens and 20s, with lower incidence in Asian and Black people than in White people. Chondrosarcoma is the most common primary malignant bone tumor in adults (about 25%) and occurs mainly in middle-aged and older adults aged 40–70. Among the limbs, osteosarcoma occurs most often around the knee (distal femur, proximal tibia) and in the proximal humerus.

5. Pathophysiology

Pathophysiology of osteosarcoma

Osteosarcoma occurs mainly around the growth plates in adolescence, which is associated with active osteoblast division during periods of rapid bone growth. In normal bone formation, osteoblasts divide and differentiate through the cell cycle, and loss of RB1 and TP53 function removes key braking mechanisms that regulate this process. RB1 inactivation abolishes the function that blocks the G1-S cell cycle transition, and TP53 mutations impair the sensing of and apoptotic response to DNA damage. This dual damage enables unlimited proliferation of abnormal osteoblasts.

Pathophysiology of Ewing sarcoma

The cell of origin of Ewing sarcoma is presumed to be primitive neuroectodermal cells or mesenchymal stem cells. The EWSR1-FLI1 fusion transcription factor activates hundreds of genes that are not normally expressed, driving a tumor-specific transcriptional program. Activation of proliferation and angiogenesis genes such as CCND1, MYC, and VEGFA is particularly central. Aberrant activation of the IGF1R signaling pathway also plays an important role in the growth of Ewing sarcoma and is a target of targeted therapy research.

Pathophysiology of chondrosarcoma

2-HG produced by IDH mutations inhibits TET2 and histone demethylases, causing hypermethylation of DNA and histones, which interferes with chondrocyte differentiation and maintains malignant chondrocytes in an undifferentiated state. Abnormalities of the hedgehog signaling pathway, such as PTCH1 and SMO, are also observed in some chondrosarcomas.

6. Symptoms

Symptoms of osteosarcoma and Ewing sarcoma

Symptoms of chondrosarcoma

Chondrosarcoma grows slowly, so symptoms progress gradually over months to years. It is often diagnosed after mild pain or swelling has persisted for a long time, and when it arises from a benign cartilage tumor that has undergone malignant transformation (enchondroma, osteochondroma), it may present with sudden worsening of symptoms.

7. Signs

Physical findings

A hard, immobile mass is palpable at the tumor site, with tenderness. Skin temperature may rise and skin color may change, and skin veins over the tumor may be dilated. In tumors adjacent to a joint, the range of motion of that joint is limited. When Ewing sarcoma invades soft tissue, extensive swelling occurs, and it is accompanied by systemic fever, which can make it difficult to differentiate from infectious lesions.

Blood test findings

Elevated serum alkaline phosphatase (ALP) is a nonspecific marker of osteosarcoma activity and is used to monitor treatment response and detect recurrence. Elevated serum lactate dehydrogenase (LDH) is a prognostic factor in Ewing sarcoma, and high LDH is associated with a poor prognosis. In Ewing sarcoma, leukocytosis and elevated C-reactive protein (CRP) can cause confusion with infectious diseases.

Imaging findings

In osteosarcoma, the sunburst pattern and Codman's triangle on X-ray are characteristic findings. In Ewing sarcoma, an onion-skin periosteal reaction is characteristic. However, a definitive diagnosis is difficult from X-ray findings alone, so MRI and tissue biopsy are essential.

8. Screening

Standard screening for primary malignant bone tumors is not recommended in the general population. However, regular checkups for early detection are considered in the following high-risk groups:

Clinically, when an adolescent has unexplained night pain, fever, or local swelling, X-ray and MRI should be performed immediately to rule out a malignant bone tumor. Even if the initial X-ray shows no abnormality, further tests including MRI are needed if symptoms persist.

9. Diagnosis

Imaging diagnosis

Plain X-ray is used for initial evaluation and assesses bone destruction, tumor bone formation, periosteal reaction, and so on. MRI is the key test for evaluating the local extent of the tumor, soft tissue invasion, its relationship to neurovascular structures, and intramedullary spread. It is essential for preoperative planning. Chest CT is used to evaluate lung metastasis, and confirming whether osteosarcoma has metastasized to the lungs is essential. PET-CT is useful for evaluating distant and bone metastasis and is particularly important for systemic staging of Ewing sarcoma.

Tissue biopsy

Bone biopsy is essential for diagnosis and, in view of later surgery, should be planned so that the direction of the biopsy incision matches the direction of the surgical incision. Percutaneous core needle biopsy is standard and should be performed by an experienced musculoskeletal tumor specialist. Incisional biopsy is performed when core needle biopsy is insufficient.

Pathology and molecular testing

Histologic type is confirmed by immunohistochemistry and molecular testing: EWSR1-FLI1 FISH or RT-PCR (Ewing sarcoma), IDH1/2 mutation analysis (chondrosarcoma), SATB2 expression (osteosarcoma). Flow cytometry is useful for confirming CD99 expression in Ewing sarcoma. For staging, the AJCC TNM system and the Enneking system are used together.

10. Treatment

Treatment of osteosarcoma

Neoadjuvant chemotherapy (MAP regimen): the combination of methotrexate (high-dose), doxorubicin (adriamycin), and cisplatin is standard. Preoperative chemotherapy shrinks the tumor, and the response to chemotherapy is assessed after surgery (tumor necrosis of 90% or more is a good response). Limb-sparing surgery: currently possible in about 90% of patients, with reconstruction after resection using a metallic prosthesis or allograft. When lung metastases are resectable, metastasectomy prolongs survival.

Treatment of Ewing sarcoma

Combination chemotherapy (alternating VDC/IE): alternating administration of vincristine+doxorubicin+cyclophosphamide (VDC) and ifosfamide+etoposide (IE) is standard. Because Ewing sarcoma is highly radiosensitive, radiation therapy is used as a substitute for surgery or as adjuvant therapy at sites where surgery is difficult or when resection margins are positive. In recurrent or refractory Ewing sarcoma, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-SCT) is performed.

Treatment of chondrosarcoma

Chondrosarcoma is relatively resistant to chemotherapy and radiation therapy, so complete surgical resection is the first-line treatment. Research on targeted therapies such as enasidenib (an IDH2 inhibitor) is under way in IDH1/2-mutant chondrosarcoma. Denosumab is used to inhibit bone destruction in giant cell tumor of bone and is also used in some chondrosarcoma-like tumors.

11. Prognosis

Tumor typeStage5-year survival
OsteosarcomaLocalized (no metastasis)60~70%
OsteosarcomaWith lung metastasis20~30%
Ewing sarcomaLocalized65~75%
Ewing sarcomaMetastaticLess than 20–30%
Chondrosarcoma (grade 1)Complete resection90% or more
Chondrosarcoma (grade 3)All stages30~50%

In osteosarcoma, good responders with tumor necrosis of 90% or more after chemotherapy have a significantly better prognosis than poor responders. Since it was confirmed that there is no difference in 5-year survival between patients who underwent limb-sparing surgery and those who underwent amputation, limb-sparing surgery for functional preservation is now standard. Most recurrences occur within 2–3 years, with lung metastasis being the most common. The prognosis after recurrence is poor, but for resectable lung metastases, long-term survival can be expected with metastasectomy.

12. Prevention


13. References